NCT00905580

Brief Summary

The investigators hypothesize that pregabalin will decrease post-operative pain scores and analgesic use following robot-assisted endoscopic thyroidectomy compared to placebo. The primary outcome will be acute postoperative pain, measured by a verbal numerical rating score (VNRS) and total analgesic consumption during postoperative 48 hours. The secondary outcome will be the incidence of chronic pain and hypoesthesia in the anterior chest at 3 months after operation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started May 2009

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2009

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

May 18, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 20, 2009

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
4 months until next milestone

Results Posted

Study results publicly available

January 11, 2010

Completed
Last Updated

January 20, 2010

Status Verified

October 1, 2009

Enrollment Period

4 months

First QC Date

May 18, 2009

Results QC Date

October 13, 2009

Last Update Submit

January 15, 2010

Conditions

Keywords

thyroidectomypain, postoperativepregabalin

Outcome Measures

Primary Outcomes (3)

  • Pain Scores (VNRS) at 1, 6, 24, 48 Hours Postoperatively.

    Pain was evaluated using an 11-point verbal numerical rating scale (VNRS). Patients were instructed preoperatively to express their pain on the 0-10 VNRS, where 0 means no pain at all, and 10 represents the worst pain imaginable

    1, 6, 24 & 48 hours

  • The Number of Participants With the Indicated Side Effects - Nausea & Vomiting, Sedation, Headache, Dizziness Etc.

    Nausea and vomiting was graded on a four-point scale, where 0 = no nausea, 1 = mild nausea, 2 = severe nausea requiring antiemetics, and 3 = retching and/ or vomiting. Grades 3 and 4 were grouped together as postoperative nausea and vomiting (PONV) and rescue anti-emetic, metoclopramide 10 mg i.v. was given. We asked patients about sedation, headache, dizziness, blurred vision.

    1, 6, 24 & 48 hours

  • Number of Patients Who Required Additional Analgesics During the First 48 Hours Postoperatively

    1, 6, 24 & 48 hours

Secondary Outcomes (1)

  • Number of Patients With Hypoesthesia in the Anterior Chest at 3 Months After Operation.

    3 months

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later

Drug: Vitamin Complex (placebo)

Pregabalin

EXPERIMENTAL

Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later

Drug: Pregabalin

Interventions

Pregabalin 150 mg orally

Pregabalin

Vitamin Complex 150 mg orally

Placebo

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesia physical status class I \& II
  • Age ≥ 20 and ≤ 65 years
  • Robot- assisted endoscopic thyroidectomy

You may not qualify if:

  • Known or suspected allergy, sensitivity, or contraindication to pregabalin or any of the standardized medications
  • Body mass index ≥ 40 kg/m2
  • History of seizure disorder
  • Current therapy with pregabalin, gabapentin, or any opioid
  • Any other physical or psychiatric condition which may impair their ability to cooperate with post-operative study data collection
  • Insulin-dependent diabetes mellitus
  • Renal insufficiency (estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine

Seoul, 120-752, South Korea

Location

Related Publications (1)

  • Kim SY, Jeong JJ, Chung WY, Kim HJ, Nam KH, Shim YH. Perioperative administration of pregabalin for pain after robot-assisted endoscopic thyroidectomy: a randomized clinical trial. Surg Endosc. 2010 Nov;24(11):2776-81. doi: 10.1007/s00464-010-1045-7. Epub 2010 Apr 8.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Pregabalin

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Results Point of Contact

Title
Dr. So Yeon Kim
Organization
Department of Anaesthesiology and Pain Medicine and Anaesthesia and Pain Research Institute, Department of surgery, Yonsei University College of Medicine

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 18, 2009

First Posted

May 20, 2009

Study Start

May 1, 2009

Primary Completion

September 1, 2009

Study Completion

September 1, 2009

Last Updated

January 20, 2010

Results First Posted

January 11, 2010

Record last verified: 2009-10

Locations